A departure from business as usual.
Around the world, the “V” words are on everyone’s lips: Virus and Vaccines.
In response to the urgent need for a vaccine for COVID-19, researchers are running hundreds of clinical trials on a number of antivirals, antibodies and vaccines.
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus.
In this whitepaper, ‘Pandemic respiratory vaccine clinical trials: A departure from business as usual’, we focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.
Download to discover: